Drug-resistant Klebsiella infections surge in European hospitals
The EU's disease agency ECDC reports that bloodstream infections caused by treatment-resistant Klebsiella pneumoniae rose 72% between 2019 and 2025. The EU had set a target of cutting such cases by 5% by 2030.

The European Centre for Disease Prevention and Control (ECDC), the EU agency that monitors infectious diseases, published its latest antimicrobial resistance reports on Wednesday. They show that a dangerous drug-resistant bacterium, Klebsiella pneumoniae, is spreading in European hospitals. Bloodstream infections caused by its treatment-resistant strains rose 72% from 2019 to 2025, even though the EU aims to cut them by 5% by 2030.
Klebsiella infections have climbed steadily for several years and pose a serious threat to hospital patients. Mortality is typically between 40% and 70%. Analyses indicate that several strains are becoming resistant to nearly all antibiotics, including new ones.
Christian Giske, who leads this work at the ECDC, told a press briefing the findings were "the biggest concern" among all the data gathered on superbugs in Europe over the past year. Antimicrobial resistance, the ability of bacteria and fungi to evolve resistance to drugs meant to destroy them, is estimated to kill 35,000 people a year in the EU, Iceland and Norway.
Why it is harder to contain
Because the bacterium spreads between patients, the ECDC calls for stronger infection prevention and control in hospitals: better hand hygiene, correct use of protective equipment such as gloves, and effective cleaning and disinfection. Similar measures have sharply reduced cases of another hospital-acquired superbug, MRSA (methicillin-resistant Staphylococcus aureus). Giske explained that Klebsiella is a gut bacterium that may have more powerful reservoirs in the body, so what works against MRSA may not be enough and adherence must be even higher.
Mixed progress
In 2025, MRSA bloodstream infections were 19% lower than in 2019, beating the 15% reduction target for 2030. Drug-resistant E. coli infections, however, rose 16.4% despite a target of a 10% cut.
Antibiotic consumption in the EU fell 5%, well short of the 20% goal. The share of correct antibiotics reached 62.5%, approaching the 65% target. ECDC Director Pamela Rendi-Wagner said several 2030 targets are still out of reach and cited genomic surveillance, which helps authorities assess more quickly how resistant bacteria spread, as a helpful innovation.
The reports come as the new EU pharmaceutical legislation, which includes measures to encourage the development of new antibiotics, is due to be signed into law in December.


